Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel for dumping syndrome after gastric surgery
NL-OMON31107Phase 4Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lanreotide in dumping syndrome, sponsored by Radboud University Medical Center. Primary endpoint: Response on dumping provocation tests. Planned start Apr 2007; status: not yet recruiting.
02
Drugs
lanreotide
03
Conditions
dumping syndrome
Beyond the preview
Go deeper on NL-OMON31107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31107.